Financial Data and Key Metrics Changes - The company reported Q2 revenue of $156.8 million and raised its full-year 2025 revenue guidance to between $625 million and $640 million, up from a previous estimate of $590 million to $600 million [4][5][11]. Business Line Data and Key Metrics Changes - The company has achieved approximately 15% penetration into its target patient population for Arclis, which is focused on recurrent pericarditis, indicating significant room for growth [5][11][34]. - The average treatment duration for Arclis is reported to be 30 months, with 45% of patients who stop therapy restarting within eight weeks due to symptom recurrence [26][27]. Market Data and Key Metrics Changes - The prescriber base for Arclis has expanded significantly, with over 3,475 prescribers by the end of Q2, reflecting a strong educational push and increased awareness of recurrent pericarditis [15][19]. - The company noted that patients often receive multiple misdiagnoses before being correctly identified as having recurrent pericarditis, highlighting the need for better education and awareness in the healthcare system [18]. Company Strategy and Development Direction - The company is focused on value creation and expanding its market presence, particularly for Arclis, which has only begun to penetrate the market [4][5]. - The development pipeline includes KPL-387, a potential monthly liquid formulation for recurrent pericarditis, expected to enter the market around 2028-2029 [6][46]. - The company is also exploring the use of Arclis in cardiac sarcoidosis, aiming to understand myocardial inflammation better through collaborations with leading medical institutions [35][36]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory of Arclis, emphasizing the importance of education and awareness in increasing prescriber confidence and patient access [19][33]. - The company remains committed to being cash flow positive annually while pursuing new indication opportunities for its pipeline products [59]. Other Important Information - The company has implemented a patient assistance program to help Medicare Part D patients afford their co-pays, which has positively impacted patient enrollment and therapy initiation [22][23]. - The company is leveraging AI and digital approaches to enhance its educational outreach to healthcare professionals and patients [20][19]. Q&A Session Summary Question: What are the growth drivers for Arclis? - The growth is driven by increased education and understanding of recurrent pericarditis among healthcare providers, leading to a broader prescriber base and higher patient enrollments [18][19]. Question: How does Medicare Part D impact patient treatment? - The changes in Medicare Part D have made therapy more affordable for patients, resulting in a one-time bolus of patients transitioning from free goods to paid therapy [22][23]. Question: What is the average treatment duration for Arclis? - The average treatment duration is reported to be 30 months, with many patients restarting therapy quickly if symptoms return [26][27]. Question: What is the strategy for KPL-387? - KPL-387 is being developed as a monthly auto-injector formulation, with strong interest from both healthcare professionals and patients, indicating a potential expansion of the market for interleukin inhibitors [40][42]. Question: What are the benefits of the Fc modified IL-1 antagonist, eleven sixty one? - The Fc modification allows for longer circulation times and potentially quarterly dosing, which could be beneficial for chronic diseases requiring long-term management [56][57].

Kiniksa Pharmaceuticals International (KNSA) Conference September 03, 2025 09:00 AM ET Company ParticipantsGeoff Meacham - Managing DirectorSanj Patel - CEO & Chairman of BoardRoss Moat - EVP & Chief Commercial OfficerJohn Paolini - EVP & Chief Medical OfficerGeoff MeachamWelcome to the second day of the Citi BioPharma Back to School Conference. This is our 20th annual. Last year we didn't do it, and we opted to put all the biotech companies in the Global Healthcare Conference in Miami. This year we're doin ...